| Evaluation of CYP1A2 activity: Relationship between the endogenous urinary 6-hydroxymelatonin to melatonin ratio and paraxanthine to caffeine ratio in dried blood spots | Clinical and translational science |  | | 2022 | 248 | 326 |
|
| Cytochrome P450 Activity Assessment: Toward Validation of Endogenous Metrics and Discovery of New Biomarkers Using Untargeted Metabolomics | |  | | 2022 | 764 | 33 |
|
| The 1β-Hydroxy-Deoxycholic Acid to Deoxycholic Acid Urinary Metabolic Ratio: Toward a Phenotyping of CYP3A Using an Endogenous Marker? | Journal of personalized medicine | | | 2021 | 230 | 72 |
|
| Metabolomics reveals biomarkers in human urine and plasma to predict cytochrome P450 2D6 (CYP2D6) activity | British journal of pharmacology | | | 2021 | 334 | 311 |
|
| The tyrosine kinase inhibitor nilotinib inhibits SARS‐CoV‐2 in vitro | Basic & Clinical Pharmacology & Toxicology | | | 2021 | 238 | 2 |
|
| Simultaneous determination of melatonin and 6-hydroxymelatonin in human overnight urine by LC-MS/MS | Journal of chromatography. B | | | 2021 | 439 | 648 |
|
| Modern approaches for the phenotyping of cytochrome P450 enzymes in children | Expert Review of Clinical Pharmacology | | | 2020 | 219 | 1 |
|
| Interaction between Fexofenadine and CYP Phenotyping Probe Drugs in Geneva Cocktail | Journal of Personalized Medicine | | | 2019 | 483 | 406 |
|
| Phenotyping of human CYP450 enzymes by endobiotics: current knowledge and methodological approaches | Clinical Pharmacokinetics | | | 2019 | 430 | 3 |
|
| Toward precision medicine in pediatric population using cytochrome P450 phenotyping approaches and physiologically based pharmacokinetic modeling | Pediatric Research | | | 2019 | 339 | 2 |
|
